The Biotech Investor: How to Profit from the Coming Boom in Biotechnology
  • Alternative view 1 of The Biotech Investor: How to Profit from the Coming Boom in Biotechnology
  • Alternative view 2 of The Biotech Investor: How to Profit from the Coming Boom in Biotechnology

The Biotech Investor: How to Profit from the Coming Boom in Biotechnology

by Tom Abate
     
 

View All Available Formats & Editions

"Tom Abate's reporting on biotechnology has always been ahead of the times. The Biotech Investor tackles the brave new world of stem cells, genomics, and clones and comes up a winner." —Thom Calandra, editor in chief, CBS MarketWatch

In The Biotech Investor, San Francisco Chronicle biotechnology reporter Tom Abate explains the

Overview

"Tom Abate's reporting on biotechnology has always been ahead of the times. The Biotech Investor tackles the brave new world of stem cells, genomics, and clones and comes up a winner." —Thom Calandra, editor in chief, CBS MarketWatch

In The Biotech Investor, San Francisco Chronicle biotechnology reporter Tom Abate explains the science, finances, time horizon, and technological and commercial potential of this burgeoning industry.
Abate provides guidelines for assessing company leadership, easy-to-digest reports from the labs, and indispensable investor tools and metrics. He shares strategies for
• tracking the effect of breaking news and the NASDAQ
• anticipating drug trial announcements and FDA approvals
• assessing the potential market, patent rights, and distribution deals for a drug
He looks beyond medicine to biotech-related opportunities in everything from agriculture to jean manufacturing to software development. The Biotech Investor is the comprehensive, expert source for successful and intelligent investing in one of the twenty-first century's most promising industries.

Editorial Reviews

From the Publisher

“An incredibly well-researched guide . . . Tom Abate is a smart independent observer, and his book will serve investors for many years to come.” —Brook H. Byers, partner, Kleiner Perkins Caufield & Byers
Publishers Weekly
With the population aging and eager for medical innovations, the market for biotechnology is vast. But for investors looking at biotech firms, it can be a minefield: before a company's brilliant ideas pan out as profitable products, they must go through years of costly research and development, clear government regulatory hurdles and sometimes, as with genetically modified foods, weather political controversy. This informative and well-written primer will help individual investors navigate the treacherous terrain of biotech stocks. Abate, a biotechnology and health care reporter for the San Francisco Chronicle, provides an overview of each sector of the biotechnology industry and the leading companies in it, tells where to find up-to-date information on the scientific and medical developments that drive the market, and explains how to evaluate the financial prospects of the often shaky start-ups that crowd the field. His advice is appropriately cautious; he suggests putting no more than 20% of a portfolio in biotechnology, and waiting until a company is in hailing distance of profitability before investing. While the book is pitched at the non-professional, Abate makes it clear that these speculative, volatile and often over-sold stocks demand more effort-he recommends reading scientific journals, attending conferences and perusing the patent literature -than a complacent mutual-fund investor is used to. But for those willing to brave the new world of biotechnology, this is a good place to start. 20 charts and graphs. (Feb.) Copyright 2003 Cahners Business Information.
Library Journal
Most investors are advised to buy and hold, but investing in biotechnology stock requires a different strategy. Because biotech medicines are experimental in nature and require strict regulatory review from the U.S. Food and Drug Administration, such investments usually are high risk, so why would anyone want to buy stocks in this sector? Abate, a biotechnology, technology, and healthcare reporter who writes a weekly "BioScope" column for the San Francisco Chronicle, here argues that the biotechnology sector has become especially interesting to investors owing to the maturation of biotech science and the aging of the population: "Companies in this industry are attacking the root causes of cancer, heart attack, Parkinson's disease and other modern scourges." Abate is forthright when discussing risk in this field and gives the reader the information needed to identify, evaluate, and invest in biotech companies. He discusses how to track stocks using the two biotech indexes on the stock exchange and indicates specific ways to search the Internet when investigating the biotechnology field. Like Jim McCamant's Biotech Investing: Every Investor's Guide, this book argues that now is the time to invest in biotech companies, but readers should remember that this is advisable only for high-risk investors. Such investors will find this book clear and understandable. Recommended for public libraries.-Bellinda Wise, Nassau Community Coll. Lib., Garden City, NY Copyright 2003 Reed Business Information.

Product Details

ISBN-13:
9780805075083
Publisher:
Holt, Henry & Company, Inc.
Publication date:
12/28/2003
Edition description:
First Edition
Pages:
304
Product dimensions:
5.50(w) x 8.50(h) x 0.69(d)

Meet the Author

One of the nation's most influential observers of the biotechnology industry, award-winning technology and health-care reporter Tom Abate writes the weekly "BioScope" column for the San Francisco Chronicle. He lives in San Leandro, California.

Customer Reviews

Average Review:

Write a Review

and post it to your social network

     

Most Helpful Customer Reviews

See all customer reviews >